4,067 Shares in Glaukos Corporation $GKOS Bought by Vise Technologies Inc.

Vise Technologies Inc. acquired a new stake in Glaukos Corporation (NYSE:GKOS) in the third quarter, Holdings Channel reports. The institutional investor acquired 4,067 shares of the medical instruments supplier’s stock, valued at approximately $668,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Glaukos during the 2nd quarter valued at $1,333,318,000. Jupiter Topco LLC bought a new stake in Glaukos in the second quarter worth $679,614,000. Janus Henderson Group PLC lifted its stake in Glaukos by 77.2% in the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock worth $575,844,000 after purchasing an additional 2,329,608 shares during the last quarter. Primecap Management Co. CA bought a new stake in Glaukos in the second quarter worth $424,969,000. Finally, William Blair Investment Management LLC bought a new stake in Glaukos in the second quarter worth $92,476,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Down 0.8%

Shares of Glaukos stock opened at $236.81 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57. Glaukos Corporation has a 52-week low of $87.32 and a 52-week high of $255.18. The company’s 50 day moving average price is $180.57 and its 200-day moving average price is $145.22. The stock has a market capitalization of $14.02 billion, a price-to-earnings ratio of -80.55 and a beta of 0.68.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.57. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The company had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. During the same period in the prior year, the business posted ($0.16) EPS. The firm’s revenue was up 58.0% compared to the same quarter last year. Equities research analysts forecast that Glaukos Corporation will post 0.50 EPS for the current year.

Analysts Set New Price Targets

GKOS has been the topic of a number of recent research reports. HC Wainwright raised their price objective on Glaukos from $195.00 to $248.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Wells Fargo & Company lifted their price objective on Glaukos from $178.00 to $226.00 and gave the stock an “overweight” rating in a report on Thursday, October 29th. BTIG Research boosted their target price on Glaukos from $205.00 to $234.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Needham & Company LLC boosted their target price on Glaukos from $201.00 to $251.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Finally, Stifel Nicolaus increased their target price on Glaukos from $190.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $216.71.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert Kliman sold 2,500 shares of the firm’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $253.00, for a total value of $632,500.00. Following the sale, the director owned 37,406 shares of the company’s stock, valued at $9,463,718. This trade represents a 6.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is currently owned by company insiders.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.